Updated UK Recommendations for HER2 assessment in breast cancer.
Bottom Line: In situ hybridisation, either fluorescent or bright field chromogenic, is used either upfront or in immunohistochemistry borderline cases to detect the presence of HER2 gene amplification.Testing laboratories should perform ongoing competency assessment and proficiency tests and ensure the reliability and accuracy of the assay.Pathologists, oncologists and surgeons involved in test interpretation and clinical use should adhere to published guidelines and maintain accurate performance and consistent interpretation of test results.
Affiliation: Department of Pathology, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, UK.Show MeSH
Related in: MedlinePlus
Mentions: Short turnaround times for HER2 testing that do not delay the management of patients are recommended. Turnaround time is recognised to be variable between different centres, and can be addressed at the level of cancer networks and local services (figure 2). The National Institute for Care Excellence recommends that HER2 status of the tumour be assessed and the results made available within 2 weeks to allow planning of systemic treatment by the MDT and that local arrangements and written clinical protocols are in place to ensure HER2 status results are available within this time (http://publications.nice.org.uk/breast-cancer-quality-standard-qs12/quality-statement-5-pathology-er-and-her2-status#quality-measure-5). It is also important to emphasise the role of improved communication between pathologists/laboratories performing the test and clinicians to ensure proper handling of specimens (ie, prefixation time and fixation type), short turnaround time and proper interpretation of the test results.
Affiliation: Department of Pathology, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, UK.